Volastra
Aliasghar Mortazi has extensive experience in the field of computer vision and image analysis, with a focus on medical imaging. Starting in 2012, they worked as a Research Assistant at Sharif University of Technology until 2014. From 2015 to 2018, they served as a Research Assistant at the University of Central Florida, where they developed customized deep learning methods for medical image analysis, including designing systems for cardiac MR/CT analysis and measuring EF automatically from cine-MR images. In 2018, Aliasghar joined Harvard Medical School as a Research Scientist Intern, where they developed deep learning algorithms for segmenting aorta from abdomen MR images and methods for Crohn's disease detection and segmentation. Aliasghar then moved to the University of Pennsylvania, where they worked as a Postdoctoral Research Fellow from 2018 to 2020, designing and implementing AI and image processing methods for disease quantification from PET/CT images. Since 2020, Aliasghar has been employed at Bioclinica as a Senior AI R&D Engineer, specializing in developing deep learning solutions for analyzing large-scale medical images, such as CT and MRI, to automate quality control and anatomical recognition in real-world applications. Aliasghar recently joined Volastra Therapeutics in 2022 as a Senior Scientist, continuing to apply their expertise in computer vision and image analytics.
Aliasghar Mortazi obtained their Bachelor's degree in Electrical and Electronics Engineering from Sharif University of Technology between the years 2012 and 2014. Aliasghar then pursued their Doctor of Philosophy (Ph.D.) in Computer Science at the University of Central Florida from 2015 to 2019.
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.